In conversation with... Rosie Bradley
from Listen to The Lancet Oncology Hosted by The Lancet
Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Listen to The Lancet Oncology?
This episode is 4 minutes long.
When was this Listen to The Lancet Oncology episode published?
This episode was published on March 1, 2022.
Can I download this Listen to The Lancet Oncology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.